Home › Tricuspid Valve Insufficiency › NCT06920745

TriClip CED RWE Study

TRIClip CoverAge With Evidence Development (CED) Real-World Evidence (RWE) Study (TRICARE)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patients ≥ 18 years of age at time of implant
* Patients with symptomatic, severe or greater Tricuspid Regurgitation who have received the TriClip system (treatment group) or have not undergone T-TEER (control group)

Exclusion Criteria:

* Patients with less than severe Tricuspid Regurgitation
* Patients with a prior history of surgical or transcatheter tricuspid valve replacement
* Patients with a surgical or transcatheter aortic or mitral valve intervention within 90 days prior to index

About the study

This Coverage with Evidence Development (CED) study evaluates the long-term health outcomes of patients with symptomatic, severe or greater Tricuspid Regurgitation who received a Tricuspid Transcatheter Edge-to-Edge Repair (T-TEER) procedure using the TriClip system.

What is being tested

• The TriClip System (device)

Sponsor: Abbott Medical Devices · Participants: 2,200 · Started: Jul 8, 2025

Contact the study team

• TRICARE · Phone: (408) 845-3000

Official record on ClinicalTrials.gov — NCT06920745

Locations in the U.S.

Conditions

• Tricuspid Valve Insufficiency

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.